Graft rejection occurred in the SAA patient who was conditioned with a fludarabine-based regimen. Grade III and grade IV acute GVHD developed in patients with AML on day 8 and day 11 acute GVHD respectively, and became a direct cause of death in one patient. The findings suggest that intensive conditioning and immunosuppression after stem cell transplantation are needed in NIMA-mismatched SCT even if donor and recipient microchimerisms is detectable in the donor and recipient before SCT.
Introduction
In allogeneic stem cell transplantation (SCT) from HLA-mismatched donors, severe acute GVHD and graft rejections occurs at he higher rate than SCT from HLA-matched donors (1, 2) . Recently, allogeneic SCT from non-inherited maternal antigen (NIMA) complementary donors has received attentions as one of the methods that potentially overcome the barrier of HLA incompatibility. It is well known that a small number of maternal blood cells exist in the newborn's blood, and in turn, blood cells derived from children can be detected in the mother's blood long after labor. This phenomenon is referred to as fetomaternal microchimerism. The existence of fetomaternal microchimerism suggests that immunological tolerance of hematopoietic cells takes place both in mother and child. Van Rood et al (3) reported the incidence of chronic GVHD was significantly lower in mother-to-child SCTs than in father-to-child SCTs.
Their findings also suggest that HLA-haploidentical NIMA complementary siblings can be alternative donor candidates when there is no HLA-matched donor. Shimazaki et al (4) reported five patients treated with allogeneic SCT from two or three loci mismatched familiy donors who had a small number of recipient-derived cells in their blood before SCT. Engraftment occurred in all patients, and although acute GVHD developed in all five, their severity was grade I or II except for one patient who developed grade III acute GVHD. Ichinohe et al (5) reported that in HLA-haploidentical SCTs, NIMA mismatches in the graft-versus-host (GVH) direction, was associated with a lower risk of severe acute GVHD compared to IPA mismatches.
Based on these backgrounds, we treated two AML patients and one SAA patient with SCT from NIMA-mismatched sibling donors. Graft rejection and severe acute GVHD occurred despite the fact that donor of recipient-derived michrochimerisms were shown in donor and recipient. He was diagnosed to have hyperacute GVHD. His skin GVHD deteriorated thus leading to a diagnosis of grade III acute GVHD. Bohrus methylprednisolone therapy could not improve the symptoms of acute GVHD. As a result, the patient died of thrombotic microangiopathy associated with acute GVHD on day 47.
Results and discussion
This study is observational. The incidence of grade II to IV acute GVHD and graft failure in patients who were transplanted from HLA haploidentical NIMA complemetary siblings has been reported to be 40-50% and 0-18% respectively (3, 5) .
Based on the results of these studies, HLA haploidentical siblings whose NIMA is complementary to that of a patient are thought to be a possible donor candidate when HLA matched donors are unavailable. However, our experience of hyperacute GVHD and graft rejection in the present report raises a concern about the efficacy of HLA-mismatched SCT from NIMA complementary siblings. Tables 1 and 2 summarize the patient characteristics and outcome of SCT for the three patients. Although the HLA disparity was one locus in the GVH direction in case 1, acute GVHD appeared on day 8 before neutrophil engraftment and rapidly progressed to grade III. Case 3 also developed hyperacute GVHD despite the fact that michrochimerism was documented in the donor's blood. Acute GVHD is known to occur frequently before engraftment of neutrophil in recipient of HLA-mismatched SCT (6, 7) . In the analysis of SCTs between NIMA-complementary family members described by Ichinohe et al (5), the presence of acute GVHD was observed from day 10.
The presence of the recipient-specific microchimerism did not necessary predict low incidence of acute GVHD in this study, in line with our experience. Our findings suggest the necessity of intensive immunosuppressive therapy to prevent acute GVHD such as ATG (9, 10) 
